A specific DNA methylation profile correlates with a high risk of disease progression in stage i classical (Alibert-Bazin type) mycosis fungoides

British Journal of Dermatology

Volumn 170, Issue 6, 2014, Pages 1266-1275

  Ferrara, G ^a   Pancione, M ^b   Votino, C ^b   Quaglino, P ^c,d   Tomasini, C ^c,d   Santucci, M ^e   Pimpinelli, N ^e   Cusano, F ^a   Sabatino, L ^b   Colantuoni, V ^b  

^a General Hospital   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; NEUROGENIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR MARKER;

ADULT; AGE; APOPTOSIS; ARTICLE; CDKN2 GENE; CELL CYCLE ARREST; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DISEASE COURSE; DISEASE SEVERITY; DNA METHYLATION; DRUG EXPOSURE; EPIGENETICS; FEMALE; FOLLOW UP; GENDER; GENE; GENE CLUSTER; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG INTERSPERSED REPEAT; MALE; MYCOSIS FUNGOIDES; NEUROG1 GENE; ONSET AGE; PPARG GENE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SOCS1 GENE; T-CELL LYMPHOMA CELL LINE; AGED; CLINICAL TRIAL; CPG ISLAND; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SKIN TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; RISK FACTORS; SKIN NEOPLASMS;

EID: 84903303627     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12717     Document Type: Article

References (40)

1. Willemze R, Kerl H, Sterry W, et al,. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1990; 90: 354-71.
2. Willemze R, Jaffe ES, Burg G, et al,. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
3. Lutzner M, Edelson R, Schein P, et al,. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 1975; 83: 534-52.
4. Vonderheid EC, Bernengo MG, Burg G, et al,. ISCL update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphoma. J Am Acad Dermatol 2002; 46: 95-106.
5. Olsen E, Vonderheid E, Pimpinelli N, et al,. ISCL/EORTC revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.
6. Kim YH, Liu HL, Mraz-Gernhard S, et al,. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-66.
7. Quaglino P, Pimpinelli N, Berti E, et al,. Gruppo Italiano Linfomi Cutanei. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classical mycosis fungoides. A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphoma. Cancer 2012; 118: 5830-9.
8. Quaglino P, Pimpinelli N, Berti E, et al,. Mycosis fungoides: disease evolution of the "lion queen" revisited. G Ital Dermatol Venereol 2012; 147: 523-31.
9. Fink-Puches R, Chott A, Ardigo' M, et al,. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol 2004; 21: 525-33.
10. Egger G, Liang G, Aparicio A, Jones PA,. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-63.
11. Ballestar E, Esteller M,. The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications. Prog Mol Subcell Biol 2005; 38: 169-81.
12. Hatziapostolou M, Iliopoulos D,. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 2011; 68: 1681-702.
13. INK4a gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 2000; 156: 1565-72.
14. Scarisbrick JJ, Woolford AJ, Calonje E, et al,. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sézary syndrome. J Invest Dermatol 2002; 118: 493-9.
15. Scarisbrick JJ, Mitchell TJ, Calonje E, et al,. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003; 121: 894-901.
16. Gallardo F, Esteller M, Pujol RM, et al,. Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. Haematologica 2004; 89: 1401-3.
17. Sommer VH, Clemmensen OJ, Nielsen O, et al,. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence of an antiapoptotic function of STAT3. Leukemia 2004; 18: 1288-95.
18. van Doorn R, Zoutman WH, Dijkman R, et al,. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTRRG, and p73. J Clin Oncol 2005; 23: 3886-96.
19. Navas IC, Algara P, Mateo M, et al,. p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides. Lab Invest 2002; 82: 123-32.
20. Li Y, Sawalha A, Lu Q,. Aberrant DNA methylation in skin diseases. J Dermatol Sci 2009; 54: 143-9.
21. Horwitz SM, Olsen EA, Duvic M, et al,. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. J Natl Compr Canc Netw 2008; 6: 436-42.
22. Pimpinelli N, Olsen EA, Santucci M, et al,. International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-63.
23. Ferrara G, Di Blasi A, Zalaudek I, et al,. Regarding the algorithm for the diagnosis of early mycosis fungoides proposed by the International Society for Cutaneous Lymphomas: suggestions from routine histopathology practice. J Cutan Pathol 2008; 35: 549-53.
24. Klemke CD, Mansmann U, Poenitz N, et al,. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005; 153: 118-24.
25. Stadler R, Otte HG, Luger T, et al,. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81.
26. Berger CL, Edelson RL,. Comparison of lymphocyte function after isolation by Ficoll-Hypaque flotation or elutriation. J Invest Dermatol 1979; 73: 231-5.
27. Bunn PA, Foss FM,. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl 1996; 24: 12-23.
28. Wang Y, Su M, Zhou LL, et al,. Deficiency of SATB1 expression in Sézary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood 2011; 117: 3826-35.
29. Pancione M, Remo A, Sabatino L, et al,. Right-sided rhabdoid colorectal tumors might be related to the serrated pathway. Diagn Pathol 2013; 8: 31.
30. Pancione M, Sabatino L, Fucci A, et al,. Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS ONE 2010; 5: e14229.
31. Chalitchagorn K, Shuangshoti S, Hourpai N, et al,. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004; 23: 8841-6.
32. Shen H, Laird PW,. Interplay between the cancer genome and epigenome. Cell 2013; 153: 38-55.
33. Smoller BR, Detwiler SP, Kohler S, et al,. Role of histology in providing prognostic information in mycosis fungoides. J Cutan Pathol 1998; 25: 311-15.
34. Ferrara G, Stefanato CM,. Mycosis fungoides with reactive lymphoid follicles may represent an early histopathologic picture of granulomatous slack skin. J Cutan Pathol 2013; 40: 611-13.
35. Yang H, Xu C, Tang Y, et al,. The significance of multiplex PCR/heteroduplex analysis-based TCR-γ gene rearrangement combined with laser-capture microdissection in the diagnosis of early mycosis fungoides. J Cutan Pathol 2012; 39: 337-46.
36. Curiel-Lewandrowski C, Yamasaki H, Si CP, et al,. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma. J Clin Invest 2011; 121: 4838-9.
37. Garcia-Bates TM, Lehmann GM, Simpson-Haidaris PJ, et al,. Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. PPAR Res 2008; 2008: 834612.
38. Cipolletta D, Feuerer M, Li A, et al,. PPARγ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012; 486: 549-53.
39. Sabatino L, Fucci A, Pancione M, Colantuoni V,. PPARG Epigenetic deregulation and its role in colorectal tumorigenesis. PPAR Res 2012; 2012: 687492.
40. Skelhorne-Gross G, Nicol CJB,. The key to unlocking the chemotherapeutic potential of PPARγ ligands: having the right combination. PPAR Res 2012; 2012: 946943.